vs
Side-by-side financial comparison of Allot Ltd. (ALLT) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
Allot Ltd. is the larger business by last-quarter revenue ($24.1M vs $18.7M, roughly 1.3× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -7.0%, a 6.2% gap on every dollar of revenue. On growth, Allot Ltd. posted the faster year-over-year revenue change (8.5% vs -25.7%). Allot Ltd. produced more free cash flow last quarter ($4.0M vs $-15.8M).
Allot Ltd., formerly Allot Communications, is an Israeli high-tech company that develops telecommunications software. The company is headquartered in Hod Hasharon, Israel.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
ALLT vs CTMX — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.1M | $18.7M |
| Net Profit | $-1.7M | $-154.0K |
| Gross Margin | 72.1% | — |
| Operating Margin | -1.7% | -6.9% |
| Net Margin | -7.0% | -0.8% |
| Revenue YoY | 8.5% | -25.7% |
| Net Profit YoY | 49.6% | 97.6% |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $24.1M | $18.7M | ||
| Q1 25 | $23.1M | $50.9M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $33.4M | ||
| Q2 24 | $22.2M | $25.1M | ||
| Q1 24 | — | $41.5M | ||
| Q4 23 | — | $26.6M | ||
| Q3 23 | — | $26.4M |
| Q2 25 | $-1.7M | $-154.0K | ||
| Q1 25 | $-332.0K | $23.5M | ||
| Q4 24 | — | $18.9M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | $-3.4M | $-6.5M | ||
| Q1 24 | — | $13.8M | ||
| Q4 23 | — | $837.0K | ||
| Q3 23 | — | $3.0M |
| Q2 25 | 72.1% | — | ||
| Q1 25 | 69.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 68.5% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q2 25 | -1.7% | -6.9% | ||
| Q1 25 | -3.1% | 44.4% | ||
| Q4 24 | — | 46.4% | ||
| Q3 24 | — | 12.3% | ||
| Q2 24 | -15.2% | -33.7% | ||
| Q1 24 | — | 28.1% | ||
| Q4 23 | — | -2.3% | ||
| Q3 23 | — | 11.8% |
| Q2 25 | -7.0% | -0.8% | ||
| Q1 25 | -1.4% | 46.2% | ||
| Q4 24 | — | 49.6% | ||
| Q3 24 | — | 17.2% | ||
| Q2 24 | -15.1% | -26.0% | ||
| Q1 24 | — | 33.3% | ||
| Q4 23 | — | 3.1% | ||
| Q3 23 | — | 11.3% |
| Q2 25 | $-0.04 | — | ||
| Q1 25 | $-0.01 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.1M | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $99.7M | $119.9M |
| Total Assets | $154.1M | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $60.1M | $49.0M | ||
| Q1 25 | $10.1M | $47.6M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $40.6M | ||
| Q2 24 | $15.9M | $43.2M | ||
| Q1 24 | — | $36.2M | ||
| Q4 23 | — | $17.2M | ||
| Q3 23 | — | $26.0M |
| Q2 25 | $99.7M | $119.9M | ||
| Q1 25 | $50.0M | $25.0M | ||
| Q4 24 | — | $-456.0K | ||
| Q3 24 | — | $-23.5M | ||
| Q2 24 | $46.7M | $-31.2M | ||
| Q1 24 | — | $-31.7M | ||
| Q4 23 | — | $-47.4M | ||
| Q3 23 | — | $-51.2M |
| Q2 25 | $154.1M | $175.1M | ||
| Q1 25 | $140.3M | $98.5M | ||
| Q4 24 | — | $120.5M | ||
| Q3 24 | — | $139.0M | ||
| Q2 24 | $132.5M | $159.2M | ||
| Q1 24 | — | $184.7M | ||
| Q4 23 | — | $201.8M | ||
| Q3 23 | — | $221.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.4M | $-15.8M |
| Free Cash FlowOCF − Capex | $4.0M | $-15.8M |
| FCF MarginFCF / Revenue | 16.5% | -84.6% |
| Capex IntensityCapex / Revenue | 1.7% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-6.0M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $4.4M | $-15.8M | ||
| Q1 25 | $1.7M | $-21.0M | ||
| Q4 24 | — | $-19.9M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | $1.2M | $-19.5M | ||
| Q1 24 | — | $-26.0M | ||
| Q4 23 | — | $-22.0M | ||
| Q3 23 | — | $-18.2M |
| Q2 25 | $4.0M | $-15.8M | ||
| Q1 25 | $1.4M | $-21.2M | ||
| Q4 24 | — | $-20.0M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | $217.0K | $-19.6M | ||
| Q1 24 | — | $-26.2M | ||
| Q4 23 | — | $-22.2M | ||
| Q3 23 | — | $-18.3M |
| Q2 25 | 16.5% | -84.6% | ||
| Q1 25 | 6.1% | -41.6% | ||
| Q4 24 | — | -52.5% | ||
| Q3 24 | — | -62.1% | ||
| Q2 24 | 1.0% | -78.2% | ||
| Q1 24 | — | -63.1% | ||
| Q4 23 | — | -83.5% | ||
| Q3 23 | — | -69.2% |
| Q2 25 | 1.7% | 0.1% | ||
| Q1 25 | 1.2% | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | 4.3% | 0.4% | ||
| Q1 24 | — | 0.3% | ||
| Q4 23 | — | 1.0% | ||
| Q3 23 | — | 0.0% |
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× | ||
| Q4 23 | — | -26.24× | ||
| Q3 23 | — | -6.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALLT
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
